NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
Roswell Park Cancer Institute
Bolt Biotherapeutics, Inc.
ImmuneSensor Therapeutics Inc.
Amgen
BioNTech SE
Omega Therapeutics
ImmuneSensor Therapeutics Inc.
SecuraBio
Fred Hutchinson Cancer Center